Models for alcohol dependence: A clinical perspective

Drug Discovery Today: Disease Models

Volumn 2, Issue 4, 2005, Pages 313-318

  Heilig, Markus ^a   Egli, Mark ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ALCOHOL; BACLOFEN; BROMOCRIPTINE; CANNABINOID RECEPTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DOPAMINE; GLUTAMIC ACID; METABOTROPIC RECEPTOR ANTAGONIST; NALTREXONE; NEUROPEPTIDE Y; ONDANSETRON; PLACEBO; RITANSERIN; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE;

ALCOHOL CONSUMPTION; ALCOHOLISM; ANIMAL MODEL; CLINICAL TRIAL; DISEASE MODEL; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; HUMAN; META ANALYSIS; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PHENOTYPE; RELAPSE; REVIEW; SYSTEMATIC REVIEW;

EID: 30444447499     PISSN: 17406757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmod.2005.11.004     Document Type: Review

References (45)

1. A.H. Mokdad et al. Actual causes of death in the United States JAMA 291 2000 1238-1245
2. M.S. Brodie et al. Ethanol increases the firing rate of dopamine neurons of the rat ventral tegmental area in vitro Brain Res. 508 1990 65-69
3. A. Imperato and G. Di Chiara Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol J. Pharmacol. Exp. Ther. 239 1986 219-228
4. N.D. Volkow et al. Effects of alcohol detoxification on dopamine D2 receptors in alcoholics: A preliminary study Psychiatry Res. 116 2002 163-172
5. A. Bowirrat and M. Oscar-Berman Relationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome Am. J. Med. Genet. B Neuropsychiatr. Genet. 132 2005 29-37
6. M. Diana et al. Enduring effects of chronic ethanol in the CNS: Basis for alcoholism Alcohol Clin. Exp. Res. 27 2003 354-361
7. T.R. Kosten et al. The potential of dopamine agonists in drug addiction Expert Opin. Investig. Drugs 11 2002 491-499
8. M.S. Brodie Increased ethanol excitation of dopaminergic neurons of the ventral tegmental area after chronic ethanol treatment Alcohol Clin. Exp. Res. 26 2002 1024-1030
9. A. Dahchour and P. De Witte Effects of acamprosate on excitatory amino acids during multiple ethanol withdrawal periods Alcohol Clin. Exp. Res. 27 2003 465-470
10. J. Littleton and W. Zieglgansberger Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence Am. J. Addict. 12 Suppl. 1 2003 S3-S11
11. R. Spanagel et al. The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption Nat. Med. 11 2005 35-42
12. G.F. Koob et al. Potential neuroprotective effects of acamprosate Alcohol Clin. Exp. Res. 26 2002 586-592
13. Egli, M. Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism? Addict. Biol. (in press)
14. G. Schulteis and G. Koob Neuropharmacology. Dark side of drug dependence Nature 371 1994 108-109
15. R. Rimondini et al. Long-lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol FASEB J. 16 2002 27-35
16. Sinclair, J.D. (1989) United States Patent Number 4,882,335. United States Patent and Trademark Office.
17. M.S. Cowen et al. The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system Addict. Biol. 10 2005 233-242
18. C.J. Heyser et al. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats Neuropsychopharmacology 18 1998 125-133
19. I. Panocka et al. 5-HT2 receptor antagonists do not reduce ethanol preference in Sardinian alcohol-preferring (sP) rats Pharmacol. Biochem. Behav. 46 1993 853-856
20. S. Maurel et al. Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats Alcohol 17 1999 195-201
21. J.R. McKay Studies of factors in relapse to alcohol, drug and nicotine use: A critical review of methodologies and findings J. Stud. Alcohol 60 1999 566-576
22. P. Bienkowski et al. Ethanol-reinforced behaviour in the rat: Effects of naltrexone Eur. J. Pharmacol. 374 1999 321-327
23. S.N. Katner et al. Reinstatement of alcohol-seeking behavior by drug-associated discriminative stimuli after prolonged extinction in the rat Neuropsychopharmacology 20 1999 471-479
24. D. Bachteler et al. The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat Neuropsychopharmacology 30 2005 1104-1110
25. M. Kornet et al. Effect of naltrexone on alcohol consumption during chronic alcohol drinking and after a period of imposed abstinence in free-choice drinking rhesus monkeys Psychopharmacology (Berl.) 104 1991 367-376
26. S.M. Holter R. Spanagel Effects of opiate antagonist treatment on the alcohol deprivation effect in long-term ethanol-experienced rats Psychopharmacology (Berl.) 145 1999 360-369
27. R. Spanagel et al. Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat Eur. J. Pharmacol. 305 1996 39-44
28. X. Liu and F. Weiss Nitric oxide synthesis inhibition attenuates conditioned reinstatement of ethanol-seeking, but not the primary reinforcing effects of ethanol Alcohol Clin. Exp. Res. 28 2004 1194-1199
29. G. Addolorato et al. Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study Alcohol Alcohol. 37 2002 504-508
30. B.A. Johnson et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients - a randomized controlled trial JAMA 284 2000 963-971
31. B.A. Johnson et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial Lancet 361 2003 1677-1685
32. Heilig, M. and Egli, M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol. Ther. (in press)
33. J. Littleton Can craving be modeled in animals? The relapse prevention perspective Addiction 95 Suppl. 2 2000 S83-S90
34. D.M. Lovinger and J.C. Crabbe Laboratory models of alcoholism: Treatment target identification and insight into mechanisms Nat. Neurosci. 8 2005 1471-1480
35. Pharmaceutical Research and Manufacturers of America What goes into the Cost of Prescription Drugs? 2005 PhRMA
36. D.T. Wong et al. Case history: The discovery of fluoxetine hydrochloride (Prozac) Nat. Rev. Drug Discov. 4 2005 764-774
37. C.R. Cloninger Neurogenetic adaptive mechanisms in alcoholism Science 236 1987 410-416
38. D.W. Oslin et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients Neuropsychopharmacology 28 2003 1546-1552
39. A. Heinz et al. Reward craving and withdrawal relief craving: Assessment of different motivational pathways to alcohol intake Alcohol Alcohol. 38 2003 35-39
40. K.D. Brownell et al. Understanding and preventing relapse Am. Psychol. 41 1986 765-782
41. D.J. Rohsenow et al. Naltrexone's effects on reactivity to alcohol cues among alcoholic men J. Abnorm. Psychol. 109 2000 738-742
42. G. Edwards M.M. Gross Alcohol dependence: Provisional description of a clinical syndrome Br. Med. J. 1 1976 1058-1061
43. M. al Qatari et al. Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain Alcohol Clin. Exp. Res. 25 2001 1276-1283
44. S. Mayer et al. Acamprosate, MK-801, and ifenprodil inhibit neurotoxicity and calcium entry induced by ethanol withdrawal in organotypic slice cultures from neonatal rat hippocampus Alcohol Clin. Exp. Res. 26 2002 1468-1478
45. J.M. Murphy et al. Phenotypic and genotypic characterization of the Indiana University rat lines selectively bred for high and low alcohol preference Behav. Genet. 32 2002 363-388